Business in Brief
JNJ completes AMO purchase, new CMO for Glaukos and more…
Ruth Steer |
- Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).
- Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).
- L. Jay Katz, director of the glaucoma service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University, has been appointed chief medical officer of Glaukos.
- Regenxbio has announced that the investigational new drug (IND) application for a Phase I trial of its wet AMD drug, RCX-314, is now active. Patient enrolment in the multicenter, open-label, multiple cohort dose escalation trial is expected to begin in Q2/Q3 of this year.
- Shire has revealed revenue of $54 million from their dry eye drug, Xiidra (lifitegrast), which launched in the USA in August 2016. Shire also announced that it has filed a New Drug Submission (NDS) with Health Canada for the marketing authorization of lifitegrast for the treatment of dry eye in adults.
- Carl Zeiss Meditec has received FDA approval of a Zeiss VisuMax software update, allowing US surgeons to perform SMILE for the correction of myopia.
- Bausch + Lomb and Nicox have resubmitted a New Drug Application to the FDA for approval of latanoprostene bunod ophthalmic solution. If approved, the single-agent eyedrop for patients with glaucoma would be the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use.
- EyeGate has entered into a licensing agreement with Valeant to allow one of Valeant’s subsidiaries worldwide commercial and manufacturing rights to the candidate EGP-437 combination product for post-operative pain and inflammation in ocular surgery patients.
- The Centers for Medicare and Medicaid Services (CMS) has announced that it will be providing up to $100 million of funding to improve education about the Quality Payment Program. The money will be awarded over the next five years to community-based organizations to provide training and educational resources on the program to small and rural practices across the USA.
- According to a press release from Ocular Therapeutix, the FDA has accepted a new drug application resubmission for its dexamethasone insert, Dextenza.
